Agenus Inc financial data

Symbol
AGEN on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3 Forbes Road, Lexington, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ANTIGENICS INC /DE/ (to 1/5/2011)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 40.6 % -63.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.6M shares -94.3%
Common Stock, Shares, Outstanding 21.1M shares
Entity Public Float 584M USD +7.24%
Common Stock, Value, Issued 211K USD -94.3%
Weighted Average Number of Shares Outstanding, Basic 21.1M shares +19.9%
Weighted Average Number of Shares Outstanding, Diluted 21.1M shares +19.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 160M USD +60.7%
Cost of Revenue 785K USD -92.6%
Research and Development Expense 199M USD -7.8%
General and Administrative Expense 73.8M USD -9.82%
Operating Income (Loss) -114M USD +45.5%
Nonoperating Income (Expense) 6.28M USD +93.1%
Earnings Per Share, Basic 1.99 USD/shares +35.9%
Earnings Per Share, Diluted 1.99 USD/shares +35.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.7M USD -34.6%
Cash, Cash Equivalents, and Short-term Investments 93.7M USD -40.7%
Accounts Receivable, after Allowance for Credit Loss, Current 719K USD -46.4%
Other Assets, Current 3.36M USD +18%
Assets, Current 100M USD -41.4%
Property, Plant and Equipment, Net 128M USD -11%
Operating Lease, Right-of-Use Asset 29M USD -5.12%
Intangible Assets, Net (Excluding Goodwill) 4.14M USD -17%
Goodwill 24.7M USD +0.08%
Other Assets, Noncurrent 6.99M USD -24.5%
Assets 292M USD -23.8%
Accounts Payable, Current 50.8M USD -3.11%
Accrued Liabilities, Current 41.2M USD +36.5%
Contract with Customer, Liability, Current 13M USD +31.5%
Liabilities, Current 271M USD +32.6%
Contract with Customer, Liability, Noncurrent 1.14M USD 0%
Operating Lease, Liability, Noncurrent 55.8M USD -10.4%
Other Liabilities, Noncurrent 1.49M USD -86.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1M USD -39.6%
Retained Earnings (Accumulated Deficit) -2.07B USD -12.1%
Stockholders' Equity Attributable to Parent -241M USD -159%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -221M USD -188%
Liabilities and Equity 292M USD -23.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +34.7%
Net Cash Provided by (Used in) Financing Activities 14.8M USD -73.6%
Net Cash Provided by (Used in) Investing Activities 229K USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 21.1M shares -94.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -23.3M USD -67.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 667K USD -19.6%
Deferred Tax Assets, Valuation Allowance 376M USD +8.23%
Cash and Cash Equivalents, Period Increase (Decrease) -44.2M USD -327%
Deferred Tax Assets, Gross 392M USD +7.54%
Operating Lease, Liability 65.1M USD -0.26%
Payments to Acquire Property, Plant, and Equipment 35K USD -98.1%
Lessee, Operating Lease, Liability, to be Paid 119M USD -6.05%
Property, Plant and Equipment, Gross 195M USD +4.42%
Operating Lease, Liability, Current 2.3M USD +20.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.1M USD +2.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.89M USD +26.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 54.2M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.85M USD -1.95%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.43M USD +4.32%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.1M USD +2.99%
Additional Paid in Capital 1.83B USD +4.52%
Deferred Tax Assets, Net of Valuation Allowance 15.8M USD -6.5%
Share-based Payment Arrangement, Expense 24.3M USD +20.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%